GALAXY and FDA Push Integrated Diagnostics Into Workflow Control

Diagnostics are moving from standalone tests to integrated platforms that control workflow, reimbursement, and treatment decisions across the care pathway.

• •Blood-first and MRD tools are becoming routine surveillance control points, not just validation studies.
• •FDA clearances are expanding diagnostics into workflow-steering infrastructure, especially in neurology and oncology.
• •CDx value now depends on access: labels, reimbursement, and network coverage determine real-world adoption.
• •AI/pathology and informatics platforms are pairing assay data with interpretation and operational control.
• •Competitive advantage is shifting to systems that can validate, deploy, and monetize tests at scale.